All News

2017

June

Media Release / Jun 27, 2017

Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases

Read More
Media Release / Jun 19, 2017

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

Read More
Media Release / Jun 15, 2017

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

Read More
Media Release / Jun 13, 2017

US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

Read More
Media Release / Jun 12, 2017

US Supreme Court clears way to early access to biosimilars

Read More

May

Media Release / May 31, 2017

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

Read More
Media Release / May 31, 2017

Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency

Read More

April

Media Release / Apr 25, 2017

Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

Read More
Media Release / Apr 21, 2017

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

Read More
Media Release / Apr 11, 2017

Major Novartis investment in Slovenia reinforces commitment to largest Sandoz product and business

Read More

Pages